1. Home
  2. RIBB vs CTSO Comparison

RIBB vs CTSO Comparison

Compare RIBB & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIBB
  • CTSO
  • Stock Information
  • Founded
  • RIBB 2024
  • CTSO 1997
  • Country
  • RIBB Japan
  • CTSO United States
  • Employees
  • RIBB N/A
  • CTSO N/A
  • Industry
  • RIBB
  • CTSO Medical/Dental Instruments
  • Sector
  • RIBB
  • CTSO Health Care
  • Exchange
  • RIBB NYSE
  • CTSO Nasdaq
  • Market Cap
  • RIBB 64.9M
  • CTSO 68.2M
  • IPO Year
  • RIBB 2025
  • CTSO N/A
  • Fundamental
  • Price
  • RIBB N/A
  • CTSO $0.87
  • Analyst Decision
  • RIBB
  • CTSO Strong Buy
  • Analyst Count
  • RIBB 0
  • CTSO 3
  • Target Price
  • RIBB N/A
  • CTSO $4.67
  • AVG Volume (30 Days)
  • RIBB 9.8K
  • CTSO 138.6K
  • Earning Date
  • RIBB 01-01-0001
  • CTSO 05-14-2025
  • Dividend Yield
  • RIBB N/A
  • CTSO N/A
  • EPS Growth
  • RIBB N/A
  • CTSO N/A
  • EPS
  • RIBB N/A
  • CTSO N/A
  • Revenue
  • RIBB N/A
  • CTSO $35,594,520.00
  • Revenue This Year
  • RIBB N/A
  • CTSO $18.72
  • Revenue Next Year
  • RIBB N/A
  • CTSO $19.75
  • P/E Ratio
  • RIBB N/A
  • CTSO N/A
  • Revenue Growth
  • RIBB N/A
  • CTSO 14.51
  • 52 Week Low
  • RIBB $9.95
  • CTSO $0.70
  • 52 Week High
  • RIBB $10.45
  • CTSO $1.61
  • Technical
  • Relative Strength Index (RSI)
  • RIBB N/A
  • CTSO 34.05
  • Support Level
  • RIBB N/A
  • CTSO $0.87
  • Resistance Level
  • RIBB N/A
  • CTSO $1.16
  • Average True Range (ATR)
  • RIBB 0.00
  • CTSO 0.06
  • MACD
  • RIBB 0.00
  • CTSO -0.02
  • Stochastic Oscillator
  • RIBB 0.00
  • CTSO 0.34

About RIBB RIBBON ACQUISITION CORP

Ribbon Acquisition Corp is a blank check company.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: